How Benzene May Lead to DLBCL
Benzene is a volatile organic compound widely used in chemical manufacturing — from printing press washes and automotive parts washers to solvents and gasoline constituents. The International Agency for Research on Cancer (IARC) classifies benzene as a Group 1 human carcinogen, and researchers have long recognized it as a cause of acute myeloid leukemia (AML) and other hematologic cancers.
The mechanisms through which benzene can induce malignancy are biologically plausible and supported by laboratory and human studies:
- Bone marrow toxicity: Benzene’s metabolites damage the bone marrow, where both myeloid cells and lymphocytes originate. This creates a toxic environment that promotes mutations and malignant transformation.
- DNA damage and chromosomal instability: Benzene metabolites generate oxidative stress and DNA adducts, interfering with normal cell replication and repair mechanisms, which can contribute to lymphomagenesis.
- Interference with immune regulation: Chronic benzene exposure disrupts normal immune signaling and could contribute to unchecked proliferation of B-cells.
Although early research focused predominantly on leukemia risk, more recent work has rigorously analyzed benzene’s link to lymphoma, particularly DLBCL.
Scientific Evidence: Benzene & DLBCL
A landmark systematic review and meta-analysis published in The Lancet Planetary Health examined all available human epidemiological studies of benzene exposure and non-Hodgkin lymphoma risk. Importantly, this analysis included both cohort and case-control studies and applied stringent selection criteria to isolate effects specific to benzene.
Key Findings
Increased NHL risk overall: Those individuals with higher benzene exposure were 33-50% more likely to develop non-Hodgkin lymphoma when compared with unexposed groups.
DLBCL risk doubled: For diffuse large B-cell lymphoma specifically, risk estimates were nearly 100% higher in highly exposed workers. This means that exposure to benzene roughly doubled the likelihood of developing DLBCL compared to individuals without significant exposure.
Consistency across studies: The findings satisfied several of the Bradford Hill criteria for causal inference, including strength of association, biological plausibility, and consistency across different study designs.
Additional cohort studies have also reported elevated mortality risks for DLBCL among benzene-exposed workers, supporting the meta-analytic results.
What This Means for Patients & Workers
Today, benzene remains a ubiquitous occupational and environmental hazard — encountered in industries such as petrochemical operations, solvent use, manufacturing, and even in environmental pollution. Even for workers outside of heavy industry, gasoline fumes and other products can expose them to incidental benzene, even if the label does not list benzene.
For people diagnosed with DLBCL who have exposed themselves to benzene for many years, these findings may matter. They can be important in medical, work, and legal situations. Understanding the causal link between benzene and lymphoma can:
- Support legal claims: Robust epidemiological evidence can help establish causation in claims alleging that benzene exposure contributed to a lymphoma diagnosis.
- Guide preventive action: Awareness of benzene’s cancer risks underscores the importance of stringent industrial hygiene, exposure monitoring, and regulatory compliance.
Seeking Help After a Diagnosis
If you or a loved one has been diagnosed with diffuse large B-cell lymphoma or other bone and blood cancers and has a history of benzene exposure at work or in the environment, the lawyers at Hughes Law Offices may be able to help.
Health outcomes from benzene exposure can be devastating, and holding responsible parties accountable, from product manufacturers to suppliers, may provide important compensation for medical costs, lost income, and quality-of-life impacts. Call 1-800-BENZENE today or contact us online for a free consultation.
